MET and cancer: In addition, overexpression of DRs such as PlexinD1 (Blanc et al, 2011), NOTCH3 (Park et al, 2006), c‐KIT (Jones et al, 2007), c‐MET (Baykal et al, 2003; Zhang et al, 2017), PTCH‐1 (Kang et al, 2013), or TrkC (Jin et al, 2007) has been reported in several cancer types, in contexts where their ligands are also expressed.